[1] |
Radin DP, Tsirka SE. Interactions between tumor cells, neurons, and microglia in the glioma microenvironment[J]. Int J Mol Sci, 2020, 21(22):8476. DOI: 10.3390/ijms21228476.
doi: 10.3390/ijms21228476
|
[2] |
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary[J]. Acta Neuropathol, 2016, 131(6):803-820. DOI: 10.1007/s00401-016-1545-1.
doi: 10.1007/s00401-016-1545-1
|
[3] |
Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10):987-996. DOI: 10.1056/NEJMoa043330.
doi: 10.1056/NEJMoa043330
|
[4] |
Alexiou GA, Tsiouris S, Kyritsis AP, et al. Glioma recurrence versus radiation necrosis: accuracy of current imaging modalities[J]. J Neurooncol, 2009, 95(1):1-11. DOI: 10.1007/s11060-009-9897-1.
doi: 10.1007/s11060-009-9897-1
|
[5] |
Haller S, Zaharchuk G, Thomas DL, et al. Arterial spin labeling perfusion of the brain: emerging clinical applications[J]. Radiology, 2016, 281(2):337-356. DOI: 10.1148/radiol.2016150789.
doi: 10.1148/radiol.2016150789
pmid: 27755938
|
[6] |
Hyare H, Thust S, Rees J. Advanced MRI techniques in the monitoring of treatment of gliomas[J]. Curr Treat Options Neurol, 2017, 19(3):11. DOI: 10.1007/s11940-017-0445-6.
doi: 10.1007/s11940-017-0445-6
|
[7] |
Macdonald DR, Cascino TL, Schold SC Jr, et al. Response criteria for phase Ⅱ studies of supratentorial malignant glioma[J]. J Clin Oncol, 1990, 8(7):1277-1280. DOI: 10.1200/JCO.1990.8.7.1277.
doi: 10.1200/JCO.1990.8.7.1277
pmid: 2358840
|
[8] |
Strauss SB, Meng A, Ebani EJ, et al. Imaging glioblastoma posttreatment: progression, pseudoprogression, pseudoresponse, radiation necrosis[J]. Radiol Clin North Am, 2019, 57(6):1199-1216. DOI: 10.1016/j.rcl.2019.07.003.
doi: 10.1016/j.rcl.2019.07.003
|
[9] |
Zikou A, Sioka C, Alexiou GA, et al. Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas[J]. Contrast Media Mol Imaging, 2018, 2018:6828396. DOI: 10.1155/2018/6828396.
doi: 10.1155/2018/6828396
|
[10] |
Razek AAKA, El-Serougy L, Abdelsalam M, et al. Differentiation of residual/recurrent gliomas from postradiation necrosis with arterial spin labeling and diffusion tensor magnetic resonance imaging-derived metrics[J]. Neuroradiology, 2018, 60(2):169-177. DOI: 10.1007/s00234-017-1955-3.
doi: 10.1007/s00234-017-1955-3
|
[11] |
Zhang J, Liu H, Tong H, et al. Clinical applications of contrast-enhanced perfusion MRI techniques in gliomas: recent advances and current challenges[J]. Contrast Media Mol Imaging, 2017, 2017:7064120. DOI: 10.1155/2017/7064120.
doi: 10.1155/2017/7064120
|
[12] |
Ye J, Bhagat SK, Li H, et al. Differentiation between recurrent gliomas and radiation necrosis using arterial spin labeling perfusion imaging[J]. Exp Ther Med, 2016, 11(6):2432-2436. DOI: 10.3892/etm.2016.3225.
doi: 10.3892/etm.2016.3225
|
[13] |
Xu Q, Liu Q, Ge H, et al. Tumor recurrence versus treatment effects in glioma: a comparative study of three dimensional pseudo-continuous arterial spin labeling and dynamic susceptibility contrast imaging[J]. Medicine (Baltimore), 2017, 96(50):e9332. DOI: 10.1097/MD.0000000000009332.
doi: 10.1097/MD.0000000000009332
|
[14] |
Larsen VA, Simonsen HJ, Law I, et al. Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis[J]. Neuroradiology, 2013, 55(3):361-369. DOI: 10.1007/s00234-012-1127-4.
doi: 10.1007/s00234-012-1127-4
|
[15] |
Shin KE, Ahn KJ, Choi HS, et al. DCE and DSC MR perfusion imaging in the differentiation of recurrent tumour from treatment-related changes in patients with glioma[J]. Clin Radiol, 2014, 69(6):e264-e272. DOI: 10.1016/j.crad.2014.01.016.
doi: 10.1016/j.crad.2014.01.016
|
[16] |
Bisdas S, Naegele T, Ritz R, et al. Distinguishing recurrent high-grade gliomas from radiation injury[J]. Acad Radiol, 2011, 18(5):575-583. DOI: 10.1016/j.acra.2011.01.018.
doi: 10.1016/j.acra.2011.01.018
|